Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty.
BACKGROUND
The projected demand for total knee arthroplasty is staggering. At its root, the solution involves increasing supply or decreasing demand. Other developed nations have used rationing and wait times to distribute this service. However, economic impact and cost-effectiveness of waiting for TKA is unknown.


METHODS
A Markov decision model was constructed for a cost-utility analysis of three treatment strategies for end-stage knee osteoarthritis: 1) TKA without delay, 2) a waiting period with no non-operative treatment and 3) a non-operative treatment bridge during that waiting period in a cohort of 60 year-old patients. Outcome probabilities and effectiveness were derived from the literature. Costs were estimated from the societal perspective with national average Medicare reimbursement. Effectiveness was expressed in quality-adjusted life years (QALYs) gained. Principal outcome measures were average incremental costs, effectiveness, and quality-adjusted life years; and net health benefits.


RESULTS
In the base case, a 2-year wait-time both with and without a non-operative treatment bridge resulted in a lower number of average QALYs gained (11.57 (no bridge) and 11.95 (bridge) vs. 12.14 (no delay). The average cost was $1,660 higher for TKA without delay than wait-time with no bridge, but $1,810 less than wait-time with non-operative bridge. The incremental cost-effectiveness ratio comparing wait-time with no bridge to TKA without delay was $2,901/QALY. When comparing TKA without delay to waiting with non-operative bridge, TKA without delay produced greater utility at a lower cost to society.


CONCLUSIONS
TKA without delay is the preferred cost-effective treatment strategy when compared to a waiting for TKA without non-operative bridge. TKA without delay is cost saving when a non-operative bridge is used during the waiting period. As it is unlikely that patients waiting for TKA would not receive non-operative treatment, TKA without delay may be an overall cost-saving health care delivery strategy. Policies aimed at increasing the supply of TKA should be considered as savings exist that could indirectly fund those strategies.
Richard C
RC
Mather
Kevin T
KT
Hug
Lori A
LA
Orlando
Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC 27710, England. tyler.watters@dm.duke.edu.
Tyler Steven
TS
Watters
Lane
L
Koenig
Ryan M
RM
Nunley
Michael P
MP
Bolognesi
D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects / Q000191:economics* / Q000401:mortality; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D017048:Health Care Costs; D015276:Health Care Rationing / Q000191:economics*; D006297:Health Services Accessibility / Q000191:economics*; D006301:Health Services Needs and Demand / Q000191:economics*; D006302:Health Services Research; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics; D008390:Markov Chains; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D018803:Models, Economic; D020370:Osteoarthritis, Knee / Q000191:economics* / Q000401:mortality / Q000601:surgery*; D018579:Patient Selection; D019057:Quality-Adjusted Life Years; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014850:Waiting Lists